VEA, IXUS, AVDV, IDVO: How to Choose Non-U.S. ETFs
A tool-first guide to four U.S.-listed non-U.S. ETFs: VEA for developed ex-U.S., IXUS for total international ex-U.S., AVDV for international small-cap value, and IDVO for quality non-U.S. stocks plus covered-call income.
This is not an abstract debate about international diversification. It is a tool-first guide: VEA for developed ex-U.S., IXUS for total international ex-U.S., AVDV for international small-cap value, and IDVO for quality non-U.S. stocks plus covered-call income.
- The main characters are four tools: VEA, IXUS, AVDV, and IDVO. They answer four different non-U.S. allocation needs.
- VEA is the lowest-cost developed ex-U.S. exposure; IXUS is the most complete one-fund total international ex-U.S. option, including emerging markets.
- AVDV is not a core holding; it is an international small-cap value factor satellite with higher volatility and a short live track record.
- IDVO is not broad-market exposure; it is quality non-U.S. stocks plus covered-call income, exchanging some upside for cash flow.
- Do not start with the ETF that recently performed best. Start with the job: low-cost developed markets, full ex-U.S. coverage, factor exposure, or income.
1. Start With the Job: What Kind of Non-U.S. Exposure Do You Need?
If your core is already VOO, VTI, or VT, you do not lack U.S. exposure. The real question is how you want to fill the non-U.S. bucket. VEA, IXUS, AVDV, and IDVO are four different answers, not four versions of the same product.
Most investors' hesitation toward "non-U.S. exposure" isn't random — behavioral finance has a name for it: home bias. Even though the U.S. makes up roughly 60% of global equity market value and non-U.S. markets together make up the other 30–40%, the typical investor's equity portfolio massively overweights their home market relative to that market-cap weight. This isn't unique to U.S. investors — retail investors in nearly every country do it — and the cost is the same everywhere: concentrating most of your net worth in one country's politics, currency, and industrial structure erodes the benefit of diversification. VEA, IXUS, AVDV, and IDVO are all, at bottom, ways of correcting this bias, just from different angles: VEA/IXUS correct geographic concentration, AVDV corrects factor concentration (over-exposure to large-cap growth), and IDVO corrects income concentration (over-reliance on capital gains with no steady distribution stream).
VEA: lowest-cost developed ex-U.S. exposure.
IXUS: one-fund total international ex-U.S., including emerging markets.
AVDV: international small-cap value factor exposure.
IDVO: quality non-U.S. stocks plus covered-call income.
Do not start with the ETF that recently performed best. Start with the role you need: developed markets, total ex-U.S., factor exposure, or income.
2. Four Tools at a Glance
| ETF | Main Role | Best Fit | Main Cost |
|---|---|---|---|
| VEA | Developed ex-U.S. core | Low-cost exposure to Japan, Europe, Canada, Australia | No emerging markets; may trail U.S. stocks |
| IXUS | Total international ex-U.S. | One-fund non-U.S. exposure including emerging markets | More emerging-market volatility and complexity |
| AVDV | International small-cap value satellite | Investors who understand factor cycles | Higher volatility, higher fee, short live record |
| IDVO | Quality non-U.S. stocks + income | Investors seeking cash flow from non-U.S. leaders | Covered calls cap some upside; higher fee |
3. VEA, IXUS, AVDV: Core, Complete, or Factor?
VEA, IXUS, and AVDV all live in the non-U.S. equity bucket, but their jobs are different.
| Item | VEA | IXUS | AVDV |
|---|---|---|---|
| Name | Vanguard Developed Markets (ex-US) | iShares Total International (ex-US) | Avantis Intl Small-Cap Value |
| Exposure | Developed ex-US (Japan, UK, Canada, France, Germany, Australia…), ~3,881 holdings | Total ex-US, ~99% of non-US market cap, ~4,380 holdings | Small-cap + value factor of developed-ex-US, ~1,730 holdings |
| Inception | 2007-07-20 | 2012-10-18 | 2019-09-24 |
| Fee | 0.03% | 0.07% | 0.36% |
| AUM | ~$222.80B | ~$56.64B | ~$19.74B |
| Avg daily volume | ~11.1M shares | ~1.1M shares | ~810k shares |
| Yield | 2.60% | 3.01% | 2.86% |
| 1-year return | +26.62% | +24.32% | +31.79% |
| Since-inception annualized | 4.94% | 7.65% | 14.59% |
| Beta | 0.84 | 0.77 | 0.78 |
| Role | Broadest developed core | Most complete "non-U.S." | More aggressive, high volatility |
Data: StockAnalysis, as of 2026-07-17/18; 1-year is total return incl. dividends. Since-inception annualized figures are not directly comparable — VEA (2007), IXUS (2012), and AVDV (2019) started at very different points, and the shorter the track record, the more it overlaps with the recent AI/tech-driven bull run (see AVDV's warning box below). All three funds' betas sit below 1 mainly because they're measured against the U.S. market, and non-U.S. markets don't move in lockstep with U.S. swings.
AVDV was launched in 2019 — less than 7 years of history — and its sample period fully encompasses the 2020–2021 global small-cap bull run. The 14.59% since-inception annualized figure (as of 2026-07-18) is highly misleading: it does not represent a full factor cycle. Fama and French's long-run academic samples estimate the small-cap and value premiums each average roughly 2%–5% per year over decades, but with huge year-to-year variance — including multi-year stretches of negative premium. Small-cap and value factors underperformed large-cap growth for a full decade (2010–2020), the most widely discussed "lost decade" in quantitative investing — a period entirely absent from AVDV's 7-year track record. Treating AVDV's short history as evidence that "international small-cap value is inherently this strong long-term" is a dangerous inference; the real question is whether you could still hold on through another stretch like 2010–2020.
That said, if you're building this satellite via periodic fixed-amount purchases (dollar-cost averaging), volatility itself isn't necessarily bad — that's a mathematical property of DCA: a fixed dollar amount buys more shares when the price is low and fewer when it's high, so over time your average cost per share equals the harmonic mean of your purchase prices, which is always lower than the simple arithmetic average price whenever the price fluctuates. In other words, the more AVDV swings around, the more a disciplined DCA buyer can push their average cost down. But there's an important caveat: this only lowers your average cost — it doesn't guarantee a profit. If the small-cap value factor structurally stops working, or the price trends down for good, a lower average cost won't rescue you from a loss; and academic comparisons of DCA versus lump-sum investing (e.g., Vanguard's 2012 analysis) actually find lump-sum wins more often in a rising market, because "getting fully invested sooner" tends to beat "waiting to buy the dip." DCA mainly solves a behavioral problem — the fear of investing everything at a local high — not a return problem.
VEA (0.03%) — the simplest, cheapest developed ex-U.S. core. It covers mature markets such as Japan, the U.K., Canada, France, Germany, and Australia, while excluding both the U.S. and emerging markets. Worth noting: "developed markets" doesn't mean "no tech exposure" — VEA's largest holdings include Samsung Electronics (~3.01%), SK Hynix (~2.57%), and ASML (~1.91%), all central players in the global semiconductor supply chain, just far more diluted than a concentrated U.S. tech bet.
IXUS (0.07%) — the most complete total ex-U.S. option. It includes both developed and emerging markets, making it the cleaner one-fund answer if you want the entire non-U.S. world in one line item. One detail that stands out for Taiwan-connected investors: because MSCI classifies Taiwan as an emerging market, TSMC is currently IXUS's single largest holding at about 4.34% — ahead of Samsung Electronics (~2.09%) and SK Hynix (~1.88%). "Ex-U.S." does not mean "ex-Taiwan"; Taiwan exposure is already built in.
AVDV (0.36%) — a factor satellite, not a lazy core. It targets developed ex-U.S. small-cap value stocks with profitability screens, designed to avoid the "cheap for a reason" value trap rather than simply buying whatever is statistically cheapest. The theory is sound, but the holding experience can be rough: long stretches of underperformance are part of factor investing.
4. IDVO: Quality Non-U.S. Stocks Plus Covered-Call Income
If Approach A is "buying the whole non-U.S. market indiscriminately," then IDVO (Amplify CWP International Enhanced Dividend Income ETF) takes the opposite road. Its most overlooked yet most compelling selling point is this — its holdings themselves are a curated list of "quality non-U.S. large caps."
It doesn't spread across the whole market; it specifically picks quality, steady dividend-paying international leaders. Open up the top 10 holdings and they're almost uniformly world-class firms whose names you'd recognize:
| # | Holding | Sector / Country | Weight |
|---|---|---|---|
| 1 | TSMC | Semiconductors / Taiwan | 5.05% |
| 2 | ASML | Semi equipment / Netherlands | 4.13% |
| 3 | Bank of Montreal (BMO) | Banking / Canada | 3.37% |
| 4 | Mitsubishi UFJ (MUFG) | Banking / Japan | 3.28% |
| 5 | Sumitomo Mitsui (SMFG) | Banking / Japan | 3.13% |
| 6 | América Móvil | Telecom / Mexico | 3.04% |
| 7 | Nutrien | Agri-chemicals / Canada | 2.99% |
| 8 | Siemens ADR | Industrials / Germany | 2.99% |
| 9 | AstraZeneca | Pharma / UK | 2.95% |
| 10 | Short-term govt money-market fund | Cash position (not a company) | 2.84% |
Top 10 holdings, StockAnalysis, as of 2026-06-16; #10 is the cash/collateral position of the covered-call strategy, not an operating company.
In other words, buying one IDVO is like holding at once semiconductor leaders (TSMC, ASML), big international banks (Japan's MUFG and SMFG, Canada's BMO), global pharma (AstraZeneca), and industrial giants (Siemens) — all solid, world-class companies outside the U.S. that you "can name and understand." For those who "want to diversify away from the U.S. but don't want to buy a basket of small companies they don't recognize," this list itself is IDVO's biggest value.
How Does It Lift the Yield to 5.67%?
Holding good companies alone wouldn't push the yield this high. IDVO's other engine is overlaying "covered calls": while holding these stocks, it sells corresponding call options, collects the premium, and folds it into the distribution. That's why its yield reaches about 5.67% (as of 2026-07-17), clearly above a plain international ETF.
| Item | IDVO |
|---|---|
| Name / issuer | Amplify CWP Intl Enhanced Dividend Income (Amplify) |
| Strategy | Global-ex-US dividend ADRs + covered calls |
| Inception | 2022-09-08 |
| Holdings | ~70 positions |
| Fee | 0.65% |
| AUM | ~$1.32B |
| Avg daily volume | ~204k shares (smaller liquidity than the other three) |
| Yield | 5.67% |
| 1-year return | +30.62% |
| Since-inception annualized | 21.49% (only ~4 years) |
| Beta | 0.68 |
Data: StockAnalysis, as of 2026-07-17/18. Highest fee and smallest AUM/liquidity of the four; only ~4 years old and fully inside a recent global bull run, so 21.49% since-inception annualized carries the same sample bias as AVDV's figure — don't treat it as a normal long-term number.
IDVO holds the stock and simultaneously sells a call option. The buyer pays a premium; IDVO turns that premium into distributable income.
Say a holding trades at 100, and IDVO sells a 3-month call at a strike of 108 for a 3 premium:
- If the stock stays at or below 108, or drifts up to 105: the option expires worthless, and IDVO simply pockets the 3 premium as extra income.
- If the stock rips to 130: IDVO must still deliver shares at the 108 strike, netting 108 + 3 (premium) = 111 — giving up 130 − 111 = 19 of the juiciest part of that rally.
That's the trade-off in a nutshell: when the stock is flat or drifts up modestly, the covered call is a steady bonus; when it rips higher, the covered call becomes a drag. So the right question for IDVO isn't "will it go up the most," but "am I willing to trade away some upside for steadier, more predictable cash flow."
① Covered calls = trading upside for income: the premium collected from selling calls isn't free — the cost is giving up part of the return in a big rally. When international stocks surge, IDVO will lag plain-holding VEA/IXUS — it swaps "the upper end of capital gains" for "steady cash flow." If you want maximum growth, this isn't your dish. In a strong bull market, the call option cap can cause IDVO to significantly lag a straightforward VEA or IXUS position. Choosing IDVO means trading some upside potential for more stable income — a legitimate trade-off, but one that should match your actual needs.
② Too new, hasn't been through a bear: listed only in September 2022; the 21.49% since-inception annualized looks impressive, but it's a product of "catching a rebound right after launch," with under four years of data — not to be read as long-term skill.
③ Higher fee, smaller liquidity: the 0.65% fee is over twenty times VEA's (0.03%); the ~204k daily volume is also far smaller than the other three — roughly a fifth of IXUS's — so watch the bid-ask spread on large trades.
That said, "smaller liquidity" matters less than it sounds for most retail investors. At a share price of roughly $41.91 and average daily volume of ~204k shares, IDVO trades about $8.5M a day — plenty for anyone dollar-cost averaging in with a few hundred to a few thousand dollars per purchase, where slippage and the bid-ask spread are barely a factor. Liquidity actually matters for those looking to deploy a lump sum in the hundreds of thousands of dollars, or who need to exit a large position quickly — that's when a smaller daily volume can genuinely affect the price you get filled at.
5. How to Combine Them: Start With the Role
| Need | Start With | Reason |
|---|---|---|
| Low-cost developed ex-U.S. exposure | VEA | Simple, cheap, mature markets |
| One-fund total international ex-U.S. | IXUS | Developed + emerging markets |
| Non-U.S. factor tilt | AVDV | Small-cap value with profitability screens |
| Non-U.S. blue chips plus cash flow | IDVO | Quality stocks + covered-call income |
If you only need a clean non-U.S. core, VEA or IXUS is enough. VEA is simpler; IXUS is more complete. AVDV and IDVO are better treated as satellites: one adds factor exposure, the other adds income design. They can have a role, but they should not become the whole story.
The practical rule is simple: assign a job before choosing the ticker. VEA or IXUS can be the non-U.S. core; AVDV is a small-cap value factor satellite; IDVO is an income satellite. Mixing all four without assigning a role to each one is not allocation discipline.
Frequently Asked Questions
📚 Further Reading
Investing involves risk; past performance does not guarantee future results; international investing carries additional currency and geopolitical risk.
Data source: StockAnalysis (VEA/IXUS/AVDV/IDVO names, inception dates, and fees are fixed values; AUM, yield, daily volume, 1-year returns, since-inception annualized, and beta as of 2026-07-17/18; IDVO top-10 holdings as of 2026-06-16, not individually re-checked). Academic citations: Eugene Fama & Kenneth French (1992), "The Cross-Section of Expected Stock Returns"; Fama & French (2015), "A Five-Factor Asset Pricing Model." The ~2%–5%/year small-cap and value premium range cited above is a rough order-of-magnitude estimate from those papers' long-run U.S. samples; actual figures vary by sample period and methodology and should be read as illustrative only. AVDV launched 2019-09-24 and does not represent a full factor cycle. IDVO launched 2022-09-08; its since-inception annualized covers a short window and is for reference only. The covered-call numeric example is a simplified illustration, not a real quote or contract term for any holding. IDVO's share price (~$41.91 at the 2026-07-17 close) and the resulting daily dollar-volume estimate are order-of-magnitude figures only; actual dollar volume varies day to day. The dollar-cost-averaging math (harmonic mean below arithmetic mean) is a statistical fact, but it does not guarantee better returns than a lump-sum approach; see Vanguard (2012), "Dollar-cost averaging just means taking risk later," for a comparison.
Comments ()